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Identification of PDE5A:E90K: A Polymorphism in the Canine
Phosphodiesterase 5A Gene Affecting Basal cGMP Concentrations
of Healthy Dogs
J. A. Stern, Y. Reina-Doreste, L. Chdid, and K. M. Meurs
Background: Cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE5A) is the target of phosphodi-
esterase inhibitors such as sildenafil. Polymorphisms in the PDE5A gene that may predict response to therapy with sildena-
fil and nitric oxide, be linked to disease progression, and aid in risk assessment have been identified in human beings.
Identification of polymorphisms in PDE5A could affect the physiologic actions of PDE5A and the effects of phosphodi-
estrase type 5 inhibitor drugs.
Hypothesis/Objective: Functional polymorphisms exist in the canine PDE5A gene. Specific objectives were to identify
PDE5A polymorphisms and evaluate their functional relevance.
Animals: Seventy healthy dogs.
Methods: The exonic, splice-site, 3′ and 5′ untranslated regions of the canine PDE5A gene were sequenced in 15 dogs
and aligned with the canine reference sequence. Identified polymorphisms were evaluated in 55 additional, healthy, unre-
lated dogs of 20 breeds. Plasma was collected from 51 of these dogs and cGMP was measured. An unpaired t-test and
one-way ANOVA with Dunnett’s test of multiple comparisons were used to evaluate the effect of genotype on cGMP.
Results: A common exonic polymorphism was identified that changed glutamic acid to lysine and resulted in signifi-
cantly lower cGMP concentrations in the group with polymorphism versus the wild type group (P = .014). Additionally, 6
linked single nucleotide polymorphisms in the 3′ untranslated region were identified that did not alter cGMP concentra-
tions.
Conclusions and Clinical Importance: A polymorphism exists in the canine PDE5A gene that is associated with variable
circulating cGMP concentrations in healthy dogs and warrants investigation in diseases such as pulmonary hypertension.
Key words: Individualized medicine; Pharmacogenomics; Pulmonary hypertension; Sildenafil citrate; Single nucleotide
polymorphisms.
Pharmacogenetics (genetic differences that affect anindividual’s response to a drug) has become an
important discipline in the management of many
human disease processes and is driving individualized
medicine.1 Despite wide variations in clinical response
to many pharmacologic agents, limited reports of
genetic polymorphisms and pharmacogenomic effects
exist in veterinary medicine.2–4
Examples of the importance of a pharmacogenetic
relationship in human beings are polymorphisms in
the phosphodiesterase 5A (PDE5A) gene that may
predict response to therapy with sildenafil and nitric
oxide, be linked to disease progression, and aid in
risk assessment in childhood IgA nephropathy, pulmo-
nary hypertension (PH), systemic hypertension, and
erectile dysfunction.5–7 The PDE5A gene encodes
a cyclic guanosine monophosphate (cGMP)-specific
phosphodiesterase. It is a key physiologic regulator of
cGMP and pharmacologic target of vasodilatory drugs
(such as sildenafil citrate) used commonly to treat PH
and erectile dysfunction.8 The coding sequence, func-
tional regions, and transcript variants of PDE5A are
well described in human beings.9,10 Additionally, the
genetic sequence of phosphodiesterase genes has been
demonstrated to be responsible for the selective action
of some phosphodiesterase inhibiting agents. When
gene segments are altered or removed, phosphodiester-
ase inhibiting agents may no longer be able to exert
their actions.11
Similar to human beings, PDE5A and drugs that
inhibit its action represent a key concept in the patho-
physiology and treatment of PH in veterinary medi-
cine. Pulmonary hypertension is a cause of respiratory
distress and collapse in dogs and defined as systolic
pulmonary arterial pressure >25 mmHg.12 It is a path-
ologic response to several pulmonary parenchymal dis-
eases and parasitic insults, and may develop secondary
to increased left atrial pressure, pulmonary blood flow,
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or increased pulmonary vascular resistance.12 In stud-
ies of the most common acquired canine heart disease
(mitral valve degeneration), 14–31% of cases have con-
current PH.13,14 Additionally, up to 20% of dogs with
PH are reported to suffer from syncopal events.12
Although it occurs secondary to multiple inciting
causes and several classification schemes have been
described, the overall prognosis and response to ther-
apy are poor in dogs with the severe form of the dis-
ease.15 In one study, median survival time was only
91 days.16 In many cases of severe PH, dogs are eutha-
nized because of failure to respond to therapy and
progressive respiratory distress.15–17 Phosphodiesterase
type V inhibitors (PDE5-I) are commonly prescribed
for PH because they increase pulmonary vascular con-
centrations of cGMP, which in turn promote endoge-
nous nitric oxide concentrations and resultant
vasodilatation.15–17
We propose genetic polymorphisms as a possible
explanation for the variable response to treatment of
PH in dogs and this study represents the first investi-
gation of PDE5A gene variation in dogs.
We hypothesized that functional polymorphisms
exist in the canine PDE5A gene. Our specific aims
included evaluation of canine PDE5A polymorphisms,
prediction of their structural consequence by computer
modeling, and evaluation of their functional relevance
in a healthy canine population by measurement of
cGMP.
Materials and Methods
DNA samples from 15 unrelated, apparently healthy dogs of 3
breeds (5 Golden Retrievers, 5 Norwich Terriers, and 5 Cavalier
King Charles Spaniels [CKCS]) were evaluated. These breeds
were chosen from the university DNA library specifically to
determine if there was any appreciable difference between geno-
types of large breed dogs (golden retrievers) versus small breed
dogs likely to be affected by mitral valve degeneration and conse-
quently PH (CKCS, Norwich Terriers). Genomic DNA samples
were prepared from whole blood samples as previously
described.18 Briefly, cells were osmotically lysed in 29 sucrose-
Triton (pH 7.6) and Tris-NH4Cl (pH 7.2) buffer, and nuclei were
pelleted by centrifugation at 380 x g for 20 min at 25°C. Pellets
were resuspended in saline-EDTA (pH 8.0) with 20% sodium
dodecyl sulfate (SDS) and 600 mAU/mL proteinase K, and incu-
bated overnight at 56°C. The samples were subjected to 2 succes-
sive phenol:chloroform:isoamyl (25:24:1, pH 8) and 1 chloroform
extraction. Finally, DNA was precipitated (in 95–100% ethanol
and 2 M NaCl) and resuspended in 100–200 lL of Tris-EDTA
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). Genomic DNA
was quantified and assessed for quality and purity based upon
spectrophotometry.a
Polymerase chain reaction (PCR) amplification primers were
designed for all exons, splice site regions, 3′ untranslated
(1,200 bp), and 5′ untranslated regions (500 bp) of the canine
PDE5A gene (ENSCAFG00000012472) using Primer 3 software
(http://frodo.wi.mit.edu/) and the canine nucleotide sequences
from the Ensembl genomic database (http://www.ensembl.org/
index.html; Table 1). Primers were designed to include the gene
promoter region and cover at least 500 upstream nucleotides
before the first reported exon. PCR was carried out using a
25 lL cocktail of molecular grade water, 109 KCL-containing
Taq buffer, 1 mM MgCl2, 0.5 units/lL of reaction volume Taq
DNA Polymerase,b 0.4 mM dNTPs, 0.4 lM PCR amplification
primers, and 100–200 lg DNA. The PCR protocol included
5 min at 95°C, 40 cycles of 94°C for 30 s, 57°C for 30 s, 72°C
for 30 s, and a final extension phase at 72°C for 7 min. The
annealing temperature was optimized for respective primers (50–
66°C). A water control (blank) with no DNA added was run
with each PCR reaction to confirm absence of DNA contamina-
tion. Successful PCR amplification was verified by loading 5 lL
of each PCR product and blank with 1 lL of agarose loading
dye on a 1.5% agarose gel and performing electrophoresis. The
amplification band was visualized by ultraviolet light to confirm
presence of the appropriately sized product for each correspond-
ing PCR primer set and the absence of any bands in the water
controls. Products were sequenced with both forward and reverse
primers and analyzed on a sequencer.c
Nucleotide sequences were evaluated visually for sequence
quality and aligned using softwared to evaluate for DNA variants
among the individual animals. Any variants identified were evalu-
ated to determine if they changed the amino acid (nonsynonom-
ous polymorphism) produced from the reference protein
sequence from the Ensembl Browser (http://www.ensembl.org/
index.html) and were in the same location as any known human
variants obtained from the Pharmacogenomics Knowledgebase
(http://www.pharmgkb.org/). If amino acid changes were
observed, their relevance was evaluated with the PolyPhen-2
program (http://genetics.bwh.harvard.edu/pph2/) to predict possi-
ble functional significance and determine the conservation of this
protein region across species.19 Additionally, functional rele-
vance was predicted by use of the Mutation Ttaster program
Table 1. PDE5A primer design. The exon or region
in PDE5A is displayed with its corresponding forward
and reverse primer utilized for PCR and sequencing.
Exon or
Region
Forward Primer
Sequence
Reverse Primer
Sequence
5′ UTR cgagggtttgtggatgtgtc gcaacatagcgagcacagaa
1 gcggtggggtcagtgag ggaactaccttctttggtgtcca
2 gcagctttcagagagagatagca tctctcctcaccccactcac
3 tcagtctttgaacaggtcagtca aaaagaaaatgtttccaaatgacc
4 tttcagccaatgaaactacca tcgctatcaacaatttcagca
5 ttggctgttgtcttacctgtttt gctaaaatgttaactggagttttaatc
6 taatgagctctaaattttcctgtct ggctaacatgaagtttaaaagcagt
7 ccacaagtattggtgttttgtg ttcagtcgtgctgttcaagg
8 ctctgttttgcccatgttttt aagtgcagatctgatgggaaa
9 agcacctaatggacaaatcaa tcaaatttacaactgaaggaaaaa
10 tttgctcaatttcttggattgtt cagagatcgagagcgtcctg
11 cattcggtagccctctcttg gatgcctccagttagtcactttt
12 tttgtgaatcactgctgcttt tccaaaggacatgattgtattcc
13 tgatacgtgttagcaagcattatt attccaatcattgttagtgcaa
14 cccatgtgaaaaacactcagaa ctggggaaaacctgccttac
15 ttgtgcagtagcccgttttt cccttttaaaattccacaacca
16 gcttctccaagtggagtgct tgcaaacacttccaagacct
17 gagcctggggactcatcata tctgacagcctcgaagatca
18 ttgggcttctttttgcctta gactcaatccagggtctcca
19 ttttactgacgtggttgaaagc ttcctaccaccaaggtctca
20 gcatgtttttggagccaact tttagcaagtctcgtgttttca
21 gggagagggcttatttcctg caaaaacctacctcagtgcaa
3′ UTR
(section 1)
ccacccactcttagcacaca cacctcaagtcaatgctcca
3′ UTR
(section 2)
tctctgagagtccgtgttttga caatgtttagcattttctatatgtgc
3′ UTR
(section 3)
cacggaagtttgggtgtgta aaaagttctttgagggtgctg
PDE5a Polymorphism Alters cGMP Concentrations 79
(www.mutationtaster.org), which reports likelihood of a mutation
to cause disease, predicts functional consequences and scores the
prediction for accuracy using a Bayes classifier.20,21
Any identified polymorphism that was predicted to be func-
tionally relevant then was evaluated in a larger cohort of appar-
ently healthy dogs, and the genotypes were recorded. This sample
group included an additional 55 unrelated dogs of 19 different
breeds (4 additional Golden Retrievers, 1 additional CKCS, 7
Labrador Retrievers, 5 American Staffordshire Terriers, 4 Minia-
ture Dachshunds, 3 Jack Russell Terriers, 2 Greyhounds, 2 Ger-
man Shepherds, 2 German Shorthair Pointers, 1 Standard
Poodle, 1 Australian Shepherd, 1 English Mastiff, 1 Boxer, 1
Basenji, 1 English Setter, 1 Border Collie, 1 German Wirehair
Pointer, 1 Chihuahua, and 16 mixed breed dogs). Additionally, a
whole-blood sample was collected in a citrated tube, and plasma
was immediately obtained by centrifugation and frozen at 80°C
in 51 of these dogs. A commercially available multi-species
cGMP EIA measurement kite was validated for use in this dog
group by confirming intra-assay precision (coefficient of variation
<10%), dilution linearity, and spike recovery in pooled canine
plasma. cGMP was measured in plasma for each of the 51 sam-
ples in duplicate by spectrophotometry and standard curve meth-
odology as previously described.22 Samples with >10% coefficient
of variation were repeated. cGMP concentrations were separated
by genotype as either wild type (matching the canine reference
sequence) or polymorphic (either positive heterozygous or posi-
tive homozygous for the polymorphism). The median, 25th and
75th percentiles are reported for each genotype category tested.
Results were evaluated statistically with an unpaired t-test and
significance was set at an alpha of <0.05 using commercially
available software.f A one-way ANOVA with Dunnett’s multiple
comparison posttest to compare genotype groups versus the con-
trol group (wild type versus heterozygous; wild type versus
homozygous) also was performed.
Results
A series of 5 linked single nucleotide polymorphisms
were identified in the 3′ untranslated region as follows:
PDE5A:g.129467A>G; g.129281T>C; g.129858C>A;
g.130270T>C; g.130311G>C; g.130515A>C. Although
SNPs within the 3′ UTR of human beings previously
have been reported and linked to progression of some
diseases, none of the identified canine SNPs in the 3′
UTR region previously have been identified in human
beings.6 This 3′ UTR SNP set of polymorphisms was
identified in a 44/70 dogs (11 homozygous, 33 hetero-
zygous, 26 wild type). Polyphen2 and Mutation Taster
predicted these SNPs to be benign and no changes to
splice sites or protein features were expected.
A single genomic variant was identified that changes
a guanine to adenine in the nucleotide sequence. This
change represents an exonic polymorphism and is pre-
dicted to change the protein’s amino acid sequence in
exon 2 from glutamic acid (E) to lysine (K) in the
polymorphic dogs (PDE5A:E90K). This change is not
reported in human beings. The reference amino acid,
glutamic acid, is acidic in nature, where as lysine is
basic. This change thus is predicted to alter the acid-
base status of the amino acid sequence within this
region of the protein from acidic to basic and was pre-
dicted to be possibly damaging by Polyphen-2 with a
HumDiv score of 0.763 (0–0.45 is benign; 0.45–0.95
possibly damaging, 0.95–1.0 probably damaging).19
The PDE5A:E90K polymorphism also changes the
amino acid within a highly conserved region of the
PDE5A gene across species (Table 2). Mutation Taster
evaluation predicted this alteration to be damaging
with an excellent probability score (0.9635/1.0).20,21
Additionally, Mutation Taster predictions find this
amino acid substitution to result in splice site changes
and possibly to alter the protein features.20,21 The
PDE5A:E90K polymorphism was identified in 61/70
dogs analyzed (21 homozygous, 40 heterozygous, 9
wild type). Known functional domains are described
for phosphodiesterase genes and PDE5A in human
beings and dogs. The PDE5A:E90K change is
upstream, adjacent to the GAF1 domain in the
PDE5A gene as reported with direct transcript evi-
dence in the UniprotKB database (www.uniprot.org).
Previously reported exonic SNPs in human beings are
reported within the GAF1 domain, but are predicted
to be benign in comparison with those reported here.6
Plasma concentrations of cGMP in 51 healthy, unre-
lated dogs (18 wild type, 18 heterozygous and 15
homozygous) demonstrated a significant difference
between PDE5A:E90K wild type and pooled polymor-
phic dogs (wild type versus combined heterozygous
and homozygous, P = .014, Fig 1), but no statistical
difference between age, sex or genotype of the 3′ UTR
SNP set. The median (25th and 75th percentiles) of
cGMP concentration of polymorphic dogs was 1.52
(1.22; 2.07) pmoles/mL, compared to wild type dogs
measured at 1.87 (1.60; 2.43) pmol/mL. When divided
into genotype classes, the heterozygous variant median
cGMP measured 1.57 (1.31; 1.88) pmol/mL, whereas
the homozygous variant median was 1.52 (0.75; 2.25).
One-way ANOVA also identified a significant differ-
ence among PDE5a:E90K genotype groups (P = .045)
with Dunnett’s test of multiple comparisons identifying
wild type versus homozygous comparison as significant
Table 2. PDE5A:E90K conservation evaluation. The
amino acid sequence surrounding the PDE5A:E90K
polymorphism is displayed in various species. The glu-
tamic acid at position 90 (E) is highly conserved
among highly varied species and seen to be substituted
by a lysine (K) in the polymorphic dog sequence only.
Amino Acid SequenceSpecies
Rat T V S F L A D S E K K E Q M P L T P P R F D N
Platypus T V S F L A D S E K K E Q M P L T P P R F D N
Opossum T V S F L A D S E K K E Q M P L T P P R F D N
Chameleon T V S F L A D S E K K E Q M P L T P P R F D N
Turkey T V S F L A D S E K K E Q M P L T P P R F D N
Chicken T V S F L A D S E K K E Q M P L T P P R F D N
Pufferfish T V S F L A D S E K K E Q M P L T P P R F D N
Frog T V S F L A D S E K K E Q M P L T P P R F D N
Human T V S F L S D S E K K E Q M P L T P P R F D N
Cat T V S F L S D S E K K E Q M P L T P P R F D N
Horse T V S F L S D S E K K E Q M P L T P P K F D N
Elephant T V S F L S D S E K K E Q M P L T P R R F D N
Dog T V S F L A D S E K K E Q M P L T P P R F D N
Mutant Dog T V S F L S D S E K K K Q M P L T P R R F D
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(P < .05; Fig 2). Heterozygous versus homozygous
variants were not significantly different. Overall, dogs
possessing the PDE5A:E90K polymorphism of either
the heterozygous or homozygous genotype had lower
basal cGMP concentrations in plasma.
Discussion
We hypothesized that functional polymorphisms in
PDE5A exist that may alter circulating cGMP concen-
trations in healthy dogs and identified 1 such poly-
morphism, PDE5A:E90K, which supports this
hypothesis. The PDE5A:E90K polymorphism is func-
tionally predicted by evaluation of conservation
(Table 2) and multiple software programs (Polyphen
2, Mutation Taster) to be damaging with conse-
quences in amino acid structure, charge, acid-base sta-
tus, potential splice site alterations, and interference
with the functional elements of the protein. The
change identified lies adjacent to the GAF1 functional
element of the protein and is in the first few nucleo-
tides of exon 2. Although the change does not lie
within the splice site, the structural prediction software
suggests the possibility that structural and acid-base
change in this region could interfere with splicing at
the RNA level. To investigate this polymorphism in
healthy dogs, basal cGMP concentrations were mea-
sured and correlated with polymorphism genotype.
The polymorphic genotype was quite common in the
canine population with more than 75% of the popula-
tion identified possessing the polymorphism in either
the heterozygous or homozygous fashion. Dogs pos-
sessing the polymorphism had lower basal, circulating
cGMP concentrations when compared with wild type
dogs.
Although the hypothesis was supported by this
study, it has several limitations. Predicting the rele-
vance of polymorphisms on protein structure and
function is difficult and imperfect. Although the mod-
els utilized are well established and the prediction was
ranked highly, modeling programs do not replace the
need for RNA and protein expression analysis, which
was not performed as part of this study and would be
necessary to confirm that the reported functional pro-
tein predictions are accurate. Additionally, because
RNA and protein expression were not evaluated, the
associated change in plasma cGMP concentration
identified in this study could represent either normal
protein concentrations with altered protein function,
directly altered protein concentrations or some combi-
nation of these possibilities. Although a significant dif-
ference was identified in plasma-circulating cGMP
concentrations, the tissue concentration of cGMP
would better represent the vasodilatory action of
cGMP. Rather than performing cell culture and intra-
cellular cGMP measurement, we chose to assess
plasma cGMP concentration as a baseline comparison
of genotype groups. This decision is supported by evi-
dence that in other species, plasma cGMP concentra-
tion is significantly correlated with aortic tissue
concentrations of cGMP in and changes in cGMP
after pharmacologic phosphodiesterase inhibition con-
tinue to correlate well.23 Additionally, the study was
performed in healthy dogs and no medical intervention
with phoshpodiesterase inhibiting drugs, additional
diagnostic tests or investigation into disease states was
performed.
Fig 1. Basal cyclic guanosine monophosphate (cGMP) concen-
trations of healthy dogs are charted by either wild type or poly-
morphic (heterozygous and homozygous) genotype. An unpaired
t-test determined these groups to be statistically different. The
P-value is shown.
Fig 2. Basal cyclic guanosine monophosphate (cGMP) concen-
trations of healthy dogs are charted by genotype (wild type, het-
erozygous, homozygous). The trend of decreased cGMP
concentration with each copy of the variant allele is observed
and the overall P-value for the one-way ANOVA demonstrates
significant difference. The asterisk denotes the statistical differ-
ence determined by Dunnett’s test of multiple comparisons
(P < .05) when comparing wild type with homozygous genotype
groups.
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Additionally, a series of 5 linked polymorphisms in
the 3′ untranslated regions were identified. Although
these changes were not predicted by Mutation Taster
or Polyphen to be damaging and were not found to
impact basal cGMP concentrations, we cannot rule
out their functional role in other physiologic processes
or disease states. A polymorphism within a different
functional unit of the human PDE5A gene has been
linked to similar findings reported here with canine
PDE5A:E90K and decreased circulating cGMP con-
centrations. This human polymorphism is further
described to blunt the magnitude of vasodilatory
response to inhaled nitric oxide.5 Additionally, the role
of the human PDE5A polymorphism is thought possi-
bly to represent a risk factor for development and pro-
gression of certain disease states such as IgA
nephropathy, essential hypertension and erectile dys-
function.5–7 In the case of the reported PDE5A:E90K
polymorphism, polymorphic dogs that possess lower
basal cGMP concentrations may generate less of a
response to drugs, such as sildenafil citrate, that typi-
cally increase cGMP to cause vasodilatation. In this
scenario, knowing that a patient possesses the poly-
morphic genotype could prompt the use of a different
vasodilatory agent or drug class.
It has been reported in multiple studies that not
only is the magnitude of response to PDE5A inhibi-
tors, such as sildenafil citrate, weak and often unsuc-
cessful in the treatment of canine PH, but it also is
apparently variable on an individual dog basis.15–17
With the exception of few pharmacogenomics discov-
ery reports, the concept of individualized medicine is
quite new for veterinary health care, but may eluci-
date the physiologic mechanism for these observa-
tions.2–4 Although this study did not set out to
identify the impact of this polymorphism in a diseased
population, it may serve as a pilot study to suggest
that the impact of this polymorphism in various dis-
ease states such as PH or systemic hypertension is
reasonable. The scope of interest may even extend
beyond that of cardiorespiratory disease because
recent investigations into PDE5A have described it as
an oncogene and possible therapeutic target in Hodg-
kin lymphoma and hepatic neoplasia.24,25 The canine
PDE5A gene possesses a least 1 amino acid-altering
polymorphism (PDE5A:E90K) that appears to confer
the functional consequence of decreased cGMP con-
centrations in healthy dogs and warrants further
investigation.
Footnotes
a Nanodrop 2000, Thermo Scientific, Wilmington, DE
b Taq DNA Polymerase, Fermentas Life Sciences, Waltham, MA
c Prism 377 Sequencer, ABI, Foster City, CA
d SeqMan Pro, DNAStar, Madison, WI
e cGMP EIA, Biomedical Technologies, Stoughton, MA
f Prism 6.0, Graphpad Software Inc, La Jolla, CA
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